Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444841 | 0.85 | DGAT1 (0.34) | MAOBTP53MDM2DGAT1MAPT | |
| SCHEMBL5247767 | 0.85 | HTR1A (0.34) | MAOBDGAT1CTNNB1 | |
| SCHEMBL5251130 | 0.85 | DGAT1 (0.31) | MAOBDGAT1 | |
| SCHEMBL5249203 | 0.82 | MAPT (0.42) | L3MBTL1DGAT1MAPTMAPK1HBB | |
| SCHEMBL19284539 | 0.81 | HSP90AB1 (0.34) | L3MBTL1MAOBTP53MDM2DGAT1 | |
| SCHEMBL2619457 | 0.80 | L3MBTL1 (0.32) | L3MBTL1TP53MDM2KDM4E | |
| SCHEMBL2136129 | 0.80 | GLA (0.37) | L3MBTL1MAOBKDM4EALDH1A1MAPT | |
| SCHEMBL2133249 | 0.78 | TP53 (0.33) | L3MBTL1TP53MDM2KDM4EALDH1A1 | |
| SCHEMBL2471286 | 0.78 | KDM4E (0.41) | MAOBDGAT1KDM4EALDH1A1MAPK1 | |
| SCHEMBL17595534 | 0.77 | DGAT1 (0.42) | L3MBTL1MAOBTP53DGAT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4359402-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117813298-A | Imidazole indazole compounds as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240092758-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2024-03-21 | — | — | US | disclosed |
| WO-2023091707-A1 | BICYCLIC INHIBITORS OF JAK AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022272020-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-3143021-B1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9518052-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | CBR3, HRH4, REN | L3MBTL1 2270/4885MAOB 1804/4885TP53 527/4885 |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | L3MBTL1 3061/4885MAOB 962/4885TP53 913/4885 |
| US-20240092758-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | L3MBTL1 3318/4885MAOB 2287/4885TP53 2071/4885 |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | JAK1, JAK3, JAK2 | L3MBTL1 3318/4885MAOB 2287/4885TP53 2071/4885 |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | L3MBTL1 3061/4885MAOB 962/4885TP53 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.